OSE Immunotherapeutics Stock Other OTC
Stocks
ORPOF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 72.49M 82.56M 66.72M 62.17M 117M 7.85B 120M 803M 311M 3.85B 310M 303M 13.41B | P/E 2026 * |
-2.37x | P/E 2027 * | -2.72x |
|---|---|---|---|---|---|
| Enterprise Value | 112M 128M 103M 96.38M 182M 12.17B 185M 1.24B 482M 5.97B 481M 470M 20.79B | EV / Sales 2026 * |
18x | EV / Sales 2027 * | 12.8x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | -15.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 2025-10-01 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 2025-08-19 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 2016-05-30 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 2017-06-13 |
| Director/Board Member | - | 2023-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.79% | -.--% | - | - | 82.56M | |
| +0.69% | +5.44% | +1.36% | +6.99% | 48.62B | |
| +0.12% | +10.45% | +408.29% | +600.97% | 39.86B | |
| +5.17% | +9.47% | +24.96% | -9.60% | 33.91B | |
| +2.02% | +4.91% | +18.59% | +63.06% | 32.32B | |
| +0.69% | +1.04% | +14.23% | +30.86% | 24.73B | |
| +0.40% | +12.51% | - | - | 16.63B | |
| +2.64% | +6.00% | +69.30% | +126.33% | 15.52B | |
| +0.58% | +0.85% | +13.52% | +18.23% | 13.63B | |
| +0.77% | +10.67% | +17.58% | -30.04% | 13.41B | |
| Average | -0.27% | +7.05% | +70.98% | +100.85% | 26.52B | |
| Weighted average by Cap. | +1.51% | +7.14% | +88.45% | +128.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.25M 7.12M 5.75M 5.36M 10.11M 677M 10.32M 69.19M 26.81M 332M 26.73M 26.15M 1.16B | 10.53M 11.99M 9.69M 9.03M 17.03M 1.14B 17.38M 117M 45.17M 560M 45.03M 44.06M 1.95B |
| Net income | -30.59M -34.84M -28.15M -26.23M -49.48M -3.31B -50.48M -339M -131M -1.63B -131M -128M -5.66B | -21.47M -24.45M -19.76M -18.41M -34.72M -2.32B -35.43M -238M -92.08M -1.14B -91.8M -89.82M -3.97B |
| Net Debt | 39.88M 45.43M 36.71M 34.21M 64.51M 4.32B 65.83M 442M 171M 2.12B 171M 167M 7.38B | 62.23M 70.88M 57.28M 53.38M 101M 6.74B 103M 689M 267M 3.31B 266M 260M 11.51B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
